Newly independent Baxalta relies heavily on hemophilia sales, particularly its top-selling Advate. As competition heats up in that market, the company has something new to brag about: Its Advate follow-up, a long-acting hemophilia A treatment called Adynovate, scored some winning data in a Phase II/III trial. More from FiercePharmaMarketing